Nu-Med Plus, Inc. 2025 Annual Report: Detailed Analysis for Investors

Key Highlights from the 2025 Annual Report

• Company Profile: Nu-Med Plus, Inc. (“NU-MED”) is a medical device company focused on the design, innovation, development, enhancement, and commercialization of quality medical devices in various stages, with an emphasis on emerging growth opportunities.
• Stock Information: The company’s common stock trades on the OTCQB under the symbol NUMD. As of April 15, 2026, the company had 83,548,469 shares of common stock outstanding. The last sale price as of June 30, 2025, was \$0.0740 per share, and \$0.0142 per share as of January 30, 2026, reflecting significant volatility.
• Corporate Status: NU-MED qualifies as both an “Emerging Growth Company” under the JOBS Act and a “Smaller Reporting Company,” allowing it to take advantage of reduced disclosure and compliance requirements compared to larger public companies.
• Going Concern Warning: The company’s independent auditors have issued a “substantial doubt” going concern opinion. This means there is significant uncertainty about NU-MED’s ability to continue operations without additional capital, which is highly material for shareholders and potential investors, and could impact the company’s share price and ability to raise funds.
• No Revenue or Net Income: The company did not report any revenue, net income, or net cash provided by operating, investing, or financing activities for the period, and has been operating at a loss. All research and development expenses are expensed as incurred, further impacting the bottom line.
• Capital Structure: NU-MED has 90,000,000 shares of common stock authorized, with 83,548,469 issued and outstanding. There are also 10,000,000 shares of preferred stock authorized, but none issued or outstanding.
• Control by Management: Current management owns approximately 15.05% of the total outstanding shares, giving them significant influence over corporate affairs, including potential mergers, asset sales, or dissolution.
• No Dividends: NU-MED has never paid, and does not expect to pay, dividends in the foreseeable future. All potential earnings will be used to fund ongoing operations and research and development.
• Absence of Equity Compensation Plans: There are no equity compensation plans currently in place, nor any outstanding options, warrants, or rights.
• Material Weakness in Internal Controls: Due to the small number of employees and lack of separation of duties, the company has declared material weaknesses in its internal controls over financial reporting.
• Competition and Regulation: The medical device business is highly competitive and heavily regulated, making it difficult and expensive for new products to enter the market.
• Risk Factors: The company’s future is dependent on its ability to raise additional capital, retain key personnel, and develop marketable medical devices despite having a management team with limited experience in bringing such devices to market.
• No Recent or Pending Legal Proceedings: There are no material legal proceedings or mining operations to report.
• Audit Firm: Fruci & Associates II, PLLC is the independent registered public accounting firm.

Critical Issues and Price-Sensitive Disclosures

• Going Concern Uncertainty: The “substantial doubt” opinion from auditors is a critical and price-sensitive disclosure. It signals significant risk regarding the company’s ability to continue operations, which could negatively impact the share price and investor confidence.
• Dependence on External Financing: The report repeatedly emphasizes that without new capital, NU-MED cannot continue operations, develop its products, or execute its business plan. The company currently has no commitments for additional capital.
• Management Control: With management holding a significant portion of shares, minority shareholders have limited influence over company decisions, which can be a concern regarding corporate governance and future strategic direction.
• Lack of Internal Controls: Material weaknesses in financial reporting controls could lead to errors, misstatements, or even fraud, which are key risks for current and potential investors.
• No Product Revenue: The absence of any product revenue to date and the lack of a clear path to commercialization are substantial concerns for the company’s valuation and attractiveness to new investors.
• No Equity Incentives: The absence of equity compensation plans may hinder the company’s ability to attract and retain essential talent.
• Stock Volatility and Low Volume: The company’s shares trade thinly and have experienced significant price fluctuations, reflecting uncertainty and risk.

Detailed Financial and Operational Analysis

Financial Position

• Assets: No significant assets are reported, including no capitalized property, plant, and equipment.
• Liabilities: The company has current liabilities, including accounts payable, but the report does not specify any long-term debt or off-balance sheet arrangements.
• Stockholders’ Deficit: The company reports a stockholders’ deficit, reflecting accumulated losses over time.

Corporate Governance and Controls

• Emerging Growth Company Benefits: As an emerging growth company and smaller reporting company, NU-MED is exempt from certain disclosure and compliance requirements, including auditor attestation of internal controls and extensive executive compensation disclosures.
• Material Weaknesses: The company lacks a formal independent audit committee and adequate separation of duties, increasing the risk of financial misstatement and limiting investor transparency.

Business and Strategic Risks

• Product Development: The company is in early- to mid-stage development of medical devices, with substantial uncertainty regarding market acceptance, regulatory approval, and commercialization.
• Key Personnel: Success depends in part on current management, which has limited experience in medical device commercialization—a significant risk factor for investors.
• Competitive Environment: The medical device sector is highly competitive and subject to regulatory hurdles, increasing the difficulty and expense of bringing new products to market.
• Product Liability: The company may be exposed to product liability claims, but management believes current insurance arrangements may not be sufficient to cover all potential claims.

Other Notable Disclosures

• No Legal Proceedings: There are no pending or threatened material legal actions against the company.
• No Mining Operations: The company has no mining operations or related risks.
• No Dividends: The company has never paid a dividend and does not expect to do so in the foreseeable future.
• No Equity Compensation: There are no equity compensation plans in place, nor any outstanding options or warrants, which could impact talent retention and attraction.
• Audit Fees: Expected audit fees for 2025 are \$18,000, with an additional \$3,750 for each quarterly review.

Conclusion: Investor Takeaways

Nu-Med Plus, Inc. remains a high-risk investment due to its lack of revenue, substantial operating losses, and uncertainty regarding its ability to continue as a going concern. The company’s reliance on external financing, absence of a clear commercialization pathway, and material weaknesses in internal controls are major red flags for investors. However, the company’s status as an emerging growth entity and smaller reporting company allows for regulatory and cost advantages that could be leveraged if it succeeds in attracting capital and talent. Investors should carefully consider these factors, along with the highly speculative nature of the medical device development business, before making any investment decisions.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult with a qualified financial advisor before making any investment in Nu-Med Plus, Inc. The information provided is based on the company’s 2025 Annual Report and may be subject to change or revision. The author and publisher are not liable for any actions taken based on the content of this article.

View Nu-Med Plus, Inc. Historical chart here